Molecular Health said today that it has raised €25 million ($26.8 million) in a private financing round led by current investor Dievini, which it will use to continue building out its commercial platform and to drive product adoption.

Molecular Health's product portfolio includes TreatmentMAP, a next-generation sequencing test for individualized tumor analysis and interpretation to help physicians select appropriate therapies for their patients; InsightMAP, which helps pharmaceutical companies optimize their drug development efforts; and SafetyMAP, which is used for individual drug de-risking and drug safety analysis.

"Big data is largely driving decision-making for today's physicians, diagnostic labs, and pharmaceutical companies," Lutz Voelker, Molecular Health's CEO said. "Our platform integrates these data into the most comprehensive biomedical data warehouse ... and quickly interprets information to generate accurate and actionable insights that drive important healthcare decisions, leading to both personalized treatment and more efficient therapy development."

With the completion of this round of financing, Molecular Health has raised a total of approximately €100 million (about $107 million), the firm said.